Stephens & Co. Maintains Overweight on Veracyte, Lowers Price Target to $55

Benzinga Newsdesk www.benzinga.com Negative 78.3%

Neg 78.3% Neu 0% Pos 0%

Stephens & Co. analyst Mason Carrico maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $68 to $55.